A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

Claire E. Wakefield; Bettina Meiser; Judi Homewood; Michelle Peate; Alan Taylor; Elizabeth Lobb; Judy Kirk; Mary Anne Young; Rachel Williams; Tracy Dudding; Kathy Tucker; K. Barlow-Stewart; G. Fenton; A. Goodwin; P. Zodgekar; L. Andrews; J. Koeler; A. Overkov; J. Tyler; B. Warner; M. Gleeson; C. Groombridge; S. O'Donnell; A. Spigelman; C. McMahon; L. Hossack; M. Kentwell; C. Aragona; R. D'Souza; C. Gaff; L. Hodgkin; R. Ward; P. Butow; H. Davey

doi:10.1007/s10549-007-9539-2

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

Claire E. Wakefield^*, Bettina Meiser, Judi Homewood, Michelle Peate, Alan Taylor, Elizabeth Lobb, Judy Kirk, Mary Anne Young, Rachel Williams, Tracy Dudding, Kathy Tucker, K. Barlow-Stewart, G. Fenton, A. Goodwin, P. Zodgekar, L. Andrews, J. Koeler, A. Overkov, J. Tyler, B. WarnerM. Gleeson, C. Groombridge, S. O'Donnell, A. Spigelman, C. McMahon, L. Hossack, M. Kentwell, C. Aragona, R. D'Souza, C. Gaff, L. Hodgkin, R. Ward, P. Butow, H. Davey

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

62 Citations (Scopus)

Abstract

Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. Results: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (χ ²(2) = 6.82; P = 0.033; χ ²(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (χ ²(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (χ ²(1) = 8.78; P = 0.003). Conclusions: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn.

Original language	English
Pages (from-to)	289-301
Number of pages	13
Journal	Breast Cancer Research and Treatment
Volume	107
Issue number	2
DOIs	https://doi.org/10.1007/s10549-007-9539-2
Publication status	Published - Jan 2008

Access to Document

10.1007/s10549-007-9539-2

Cite this

Wakefield, C. E., Meiser, B., Homewood, J., Peate, M., Taylor, A., Lobb, E., Kirk, J., Young, M. A., Williams, R., Dudding, T., Tucker, K., Barlow-Stewart, K., Fenton, G., Goodwin, A., Zodgekar, P., Andrews, L., Koeler, J., Overkov, A., Tyler, J., ... Davey, H. (2008). A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Research and Treatment, 107(2), 289-301. https://doi.org/10.1007/s10549-007-9539-2

@article{852c907efdac47a084cba7790d88332d,

title = "A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk",

abstract = "Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. Results: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (χ 2(2) = 6.82; P = 0.033; χ 2(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (χ 2(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (χ 2(1) = 8.78; P = 0.003). Conclusions: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn.",

author = "Wakefield, {Claire E.} and Bettina Meiser and Judi Homewood and Michelle Peate and Alan Taylor and Elizabeth Lobb and Judy Kirk and Young, {Mary Anne} and Rachel Williams and Tracy Dudding and Kathy Tucker and K. Barlow-Stewart and G. Fenton and A. Goodwin and P. Zodgekar and L. Andrews and J. Koeler and A. Overkov and J. Tyler and B. Warner and M. Gleeson and C. Groombridge and S. O'Donnell and A. Spigelman and C. McMahon and L. Hossack and M. Kentwell and C. Aragona and R. D'Souza and C. Gaff and L. Hodgkin and R. Ward and P. Butow and H. Davey",

year = "2008",

month = jan,

doi = "10.1007/s10549-007-9539-2",

language = "English",

volume = "107",

pages = "289--301",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer, Springer Nature",

number = "2",

}

Wakefield, CE, Meiser, B, Homewood, J, Peate, M, Taylor, A, Lobb, E, Kirk, J, Young, MA, Williams, R, Dudding, T, Tucker, K, Barlow-Stewart, K, Fenton, G, Goodwin, A, Zodgekar, P, Andrews, L, Koeler, J, Overkov, A, Tyler, J, Warner, B, Gleeson, M, Groombridge, C, O'Donnell, S, Spigelman, A, McMahon, C, Hossack, L, Kentwell, M, Aragona, C, D'Souza, R, Gaff, C, Hodgkin, L, Ward, R, Butow, P & Davey, H 2008, 'A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk', Breast Cancer Research and Treatment, vol. 107, no. 2, pp. 289-301. https://doi.org/10.1007/s10549-007-9539-2

TY - JOUR

T1 - A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

AU - Wakefield, Claire E.

AU - Meiser, Bettina

AU - Homewood, Judi

AU - Peate, Michelle

AU - Taylor, Alan

AU - Lobb, Elizabeth

AU - Kirk, Judy

AU - Young, Mary Anne

AU - Williams, Rachel

AU - Dudding, Tracy

AU - Tucker, Kathy

AU - Barlow-Stewart, K.

AU - Fenton, G.

AU - Goodwin, A.

AU - Zodgekar, P.

AU - Andrews, L.

AU - Koeler, J.

AU - Overkov, A.

AU - Tyler, J.

AU - Warner, B.

AU - Gleeson, M.

AU - Groombridge, C.

AU - O'Donnell, S.

AU - Spigelman, A.

AU - McMahon, C.

AU - Hossack, L.

AU - Kentwell, M.

AU - Aragona, C.

AU - D'Souza, R.

AU - Gaff, C.

AU - Hodgkin, L.

AU - Ward, R.

AU - Butow, P.

AU - Davey, H.

PY - 2008/1

Y1 - 2008/1

N2 - Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. Results: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (χ 2(2) = 6.82; P = 0.033; χ 2(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (χ 2(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (χ 2(1) = 8.78; P = 0.003). Conclusions: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn.

AB - Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. Results: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (χ 2(2) = 6.82; P = 0.033; χ 2(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (χ 2(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (χ 2(1) = 8.78; P = 0.003). Conclusions: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn.

UR - http://www.scopus.com/inward/record.url?scp=37249025159&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9539-2

DO - 10.1007/s10549-007-9539-2

M3 - Article

C2 - 17333332

AN - SCOPUS:37249025159

SN - 0167-6806

VL - 107

SP - 289

EP - 301

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

Abstract

Access to Document

Other files and links

Fingerprint

Cite this